Adds details on injection intervals, expected approval timing, shares
May 23 (Reuters) - German drugmaker Bayer BAYGn.DE on Friday won an endorsement by the European Medicines Agency to extend the intervals between shots of its anti-blindness treatment Eylea, giving it a potential edge over Roche's ROG.S rival treatment Vabysmo.
Bayer said in a statement the European Medicines Agency recommended that eye drug Eylea, at a high dose of 8 mg, can be injected at intervals of up to six months to treat wet age-related macular degeneration and diabetic macular oedema.
Bayer shares were up 2.5% at 0717 GMT, surpassing a gain of 0.7% in the Stoxx Europe 600 Health Care index.
Eylea, an injection against the leading causes of blindness among the elderly, is currently approved in the EU for treatment intervals of up to five months. Bayer has developed it jointly with Regeneron REGN.O.
Vabysmo, a major driver of revenue growth for Switzerland's Roche, is cleared to be given at intervals of up to four months.
The EU commission has the final say on drug approval but it typically follows the medicines agency's opinions. Bayer said that decision is expected within the next few weeks.
(Reporting by Ludwig Burger, Editing by Friederike Heine)
((ludwig.burger@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.